| Name | Title | Contact Details |
|---|
OXiGENE is a biopharmaceutical company developing new and improved therapeutics that have the potential to deliver significant medical benefits to patients with cancer and serious medical conditions. Our primary focus is developing first-in-class anti-vascular drugs referred to as vascular disrupting agents (VDAs). Our lead compound in clinical development is fosbretabulin. VDAs are a new and highly differentiated class of anti-vascular drug that target existing tumor vasculature, leading to extensive tumor cell death. VDAs target the tumor vasculature rather than the tumor cells and therefore have broad potential therapeutic utility in cancer. Because VDAs act differently than anti-angiogenic drugs or cytotoxic chemotherapy drugs, VDAs are potentially complementary with anti-angiogenic drugs and chemotherapeutic agents. OXiGENE has ongoing VDA drug development programs and is committed to advancing the science of VDAs and their potential as innovative therapies to address unmet medical needs.
Nipro Diagnostics is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
If you suffer from chronic pain or aching in your knee, you may have osteoarthritis (OA) – a painful joint condition that can interfere with nearly all aspects of daily life. Right now, doctors at select centers in the U.S. are accepting participants for the Atlas Clinical Trial. The trial is for the Atlas System – an investigational device designed to relieve knee pain, while preserving your joint’s natural anatomy and motion.
Symbios Medical Products is a Indianapolis, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Century Pacific is a Lake Forest, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.